NCT01169558 - A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum. | Biotech Hunter

Enrollment

168

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions

Colorectal Cancer

Interventions

DRUG

Bevacizumab

5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.

DRUG

Fluoropyrimidine-based Chemotherapy

Fluoropyrimidine-based chemotherapy administered according to standard of care.

Trial Locations (28)

22031072

Rio de Janeiro

30150321

Belo Horizonte

58040280

João Pessoa

30140-083

Belo Horizonte

30150-221

Belo Horizonte

70390-150

Brasília

70710-904

Brasília

13073-400

Campinas

13084-759

Campinas

95020-450

Caxias do Sul

80530-010

Curitiba

80730-180

Curitiba

60741-420

Fortaleza

98700-000

Ijuí

90020-090

Porto Alegre

90035-903

Porto Alegre

52012-220

Recife

14025-430

Ribeirão Preto

22631-004

Rio de Janeiro

40170-110

Salvador

41810-012

Salvador

41950-610

Salvador

01229-000

São Paulo

01232-010

São Paulo

01332-000

São Paulo

01406100

São Paulo

04122-000

São Paulo

05651-901

São Paulo

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY